Pancreatic Cancer Research

ResearcherHarvard UniversityNo recent work listed

Rebecca Anne Miksad

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-3194-5122; OpenAlex author ID A5035601295. Sources: ClinicalTrials.gov.

Their work

Papers
10 (first author 2, last author 2)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
43
Papers, trials and grants by year

2004: 1 trial · 2005: none · 2006: none · 2007: none · 2008: none · 2009: none · 2010: none · 2011: none · 2012: none · 2013: none · 2014: none · 2015: none · 2016: 4 papers · 2017: 3 papers · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 1 paper

Papers 10

  1. Early-onset pancreatic cancer research: Making sense of confounding and bias. Co-author DOI 10.1002/cncr.33663↗
  2. Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States. First author DOI 10.1097/mpa.0000000000001479↗
  3. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamaoncol.2017.3420↗
  4. Regional variation in the treatment of pancreatic adenocarcinoma: Decreasing disparities with multimodality therapy. Co-author DOI 10.1016/j.surg.2017.03.009↗
  5. Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival. Co-author DOI 10.1038/bjc.2017.349↗
  6. Capecitabine and oxaliplatin as first and second line treatment for locally advanced and metastatic pancreatic ductal adenocarcinoma. Last author DOI 10.21037/jgo.2017.06.06↗
  7. Genetic Testing in Pancreatic Ductal Adenocarcinoma: Implications for Prevention and Treatment. Last author DOI 10.1016/j.clinthera.2016.03.006↗
  8. Neoadjuvant therapy versus upfront surgical strategies in resectable pancreatic cancer: A Markov decision analysis. Co-author DOI 10.1016/j.ejso.2016.07.016↗
  9. Cutting Through Confusion: Multimodality Therapy in Borderline Resectable and Locally Advanced Pancreatic Cancer. First author DOI 10.1200/jop.2016.016923↗
  10. Meta-analysis of transcriptome data identifies a novel 5-gene pancreatic adenocarcinoma classifier. Co-author DOI 10.18632/oncotarget.8139↗

Trials 1

  1. Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma Principal investigator NCT00585078↗

Closest collaborators

The 25 strongest of 43 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jennifer F. Tseng · 6 shared papers, 2016–2018 · strength 0.42
  2. Gregory Sampang Calip · 1 shared paper, 2021 · strength 0.28
  3. Andrea J. Bullock · 4 shared papers, 2016–2018 · strength 0.22
  4. Gyulnara G. Kasumova · 2 shared papers, 2016–2017 · strength 0.17
  5. Mariam F. Eskander · 2 shared papers, 2016–2017 · strength 0.13
  6. Susanna W.L. de Geus · 2 shared papers, 2016–2017 · strength 0.13
  7. Afsaneh Barzi · 1 shared paper, 2020 · strength 0.11
  8. Daniel H. Ahn · 1 shared paper, 2020 · strength 0.11
  9. Tanios Bekaii‐Saab · 1 shared paper, 2020 · strength 0.11
  10. Mary Linton B. Peters · 1 shared paper, 2016 · strength 0.10
  11. Ana Babić · 2 shared papers, 2017–2018 · strength 0.10
  12. David C. Linehan · 2 shared papers, 2017–2018 · strength 0.10
  13. Albert C. Koong · 2 shared papers, 2017–2018 · strength 0.10
  14. Chen Yuan · 2 shared papers, 2017–2018 · strength 0.10
  15. Richard Francis Dunne · 2 shared papers, 2017–2018 · strength 0.10
  16. Thomas E. Clancy · 2 shared papers, 2017–2018 · strength 0.10
  17. Douglas Adam Rubinson · 2 shared papers, 2017–2018 · strength 0.10
  18. Vicente Morales‐Oyarvide · 2 shared papers, 2017–2018 · strength 0.10
  19. Kimmie Ng · 2 shared papers, 2017–2018 · strength 0.10
  20. Margaret M. Kozak · 2 shared papers, 2017–2018 · strength 0.10
  21. Zhi Rong Qian · 2 shared papers, 2017–2018 · strength 0.10
  22. Daniel Tandel Chang · 2 shared papers, 2017–2018 · strength 0.10
  23. Aram F. Hezel · 2 shared papers, 2017–2018 · strength 0.10
  24. Brian Matthew Wolpin · 2 shared papers, 2017–2018 · strength 0.10
  25. Jonathan Andrew Nowak · 2 shared papers, 2017–2018 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.